Abstract:Rheumatoid arthritis(RA)is a common chronic,systemic autoimmune disease characterized by erosive arthritis,with a global prevalence of 0.25%to 1.00%,which may ultimately lead to joint deformity and loss of function.An-tinuclear antibody(ANA)refers to auto-antibodies that target various components of eukaryotic cells.Although ANA may be frequently detected in RA patients,with a positive rate of 30%to 60%,the significance of ANA in the diagnosis and treatment of RA remains unclear.Nuclear patterns in RA population are dominated by speckled and homogeneous patterns,mainly at low titres.The detection rate of extractable nuclear antibodies is usually lower than that of ANA.The serum levels of rheumatoid factor and anti-cyclic citrullinated peptide antibody in ANA-positive RA patients are much higher than ANA-negative ones,and joint erosion of ANA-positive RA patients had more severe joint erosion on imaging as well.Therefore,ANA is a potential predictor of severe joint injury.ANA-positive RA patients are more likely to have extra-articular mani-festations[such as subcutaneous nodules(82%vs 46%),ocular lesions(38%vs 6%),and infections(38%vs 12%)].In terms of RA comorbidities,compared to the ANA negative group,the ANA positive group had higher levels of moderate and se-vere anemia(16.04%vs 6.9%;6.6%vs 0.07%),Sjogren's syndrome(19.5%vs 4.1%),and vasculitis(29%vs 7%).In addi-tion,ANA positivity is an independent risk factor for elderly RA patients with carotid intimal thickening(HR=4.089)and adverse pregnancy outcomes in female RA(OR=3.268,P=0.045),respectively.Attention should be paid to high-titre ANA-positive RA patients for preventive measures.In terms of treatment,RA patients who are ANA-positive when given tumour necrosis factor-α inhibitor(TNFi)treatment got much poorer therapeutic response than ANA-negative ones,especially those with high titres were more prone to generating anti-drug antibodies.Increase of ANA titer induced by TNFi is associated with no response to TNFi treatment,thus monitoring the change of ANA may predict the long-term efficacy of TNFi.The most common adverse event of TNFi is drug-induced lupus.Although it has been confirmed that the induction of anti-double-stranded DNA antibodies is associated with poor efficacy of TNFi,large-scale studies are still needed to confirm the corre-lation between the increase of ANA titer or ocurence of dsDNA antibody and the induction of drug-induced lupus.In con-clusion,this paper reviews the research progress on ANA characteristics in RA population,clinical manifestations of ANA-positive RA,and the association between ANA and TNFi prognosis.The potential of ANA as a new biomarker of RA needs to be further studied.

Antinuclear antibodies in neurology and their clinical application

Antinuclear antibodies (ANA): immunologic and clinical significance

CLINICAL AND DIAGNOSTIC VALUE OF ANTINUCLEAR ANTIBODIES IN A PEDIATRIC PHYSICIAN’S PRACTICE (PART 2)

Effect of antinuclear antibody positivity on antineutrophil cytoplasmic antibody results by indirect immunofluorescence assay

Utility of Antinuclear Antibody Screening by Various Methods in a Clinical Laboratory Patient Cohort

Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others

Autoimmune central nervous system disorders: Antibody testing and its clinical utility

Comprehensive Exploration of Antinuclear Antibodies (ANAs): Unveiling Clinical Significance, Associations with Cancer, and the Nuances of Differential Diagnosis in Positive ANA Patients

Autoimmune Neuromuscular Disorders Associated With Neural Antibodies

Clinical research on progress of antinuclear antibody in rheumatoid arthritis

A Clinical Study of Thyroid Abnormalities and Autoantibodies in Patients Diagnosed With Anti-nuclear Antibody Positive Autoimmune Connective Tissue Disorders: An Observational Cross-Sectional Study

CLINICAL AND DIAGNOSTIC VALUE OF ANTINUCLEAR ANTIBODIES IN A PEDIATRIC PHYSICIAN’S PRACTICE (PART 3)

Anti-neuronal nuclear autoantibodies, types 1 and 2: their utility in the study of tumors of the nervous system

Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP

Overview and Diagnostic Approach in Autoimmune Neurology

Antinuclear antibody screening in this new millennium: farewell to the microscope?

Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test

Clinical application of autoimmune neurological diseases related antibodies

Clinical Performance of the Line Immunoassay, Digital Liquid Chip Method, and Chemiluminescent Immunoassay for Detecting Specific Antinuclear Antibodies.

Evaluation on the Detection of Anti-Nuclear Antibody and Anti-Soluble Nuclearantigen Antibody for the Diagnosis of Autoimmune Disease

Using Antinuclear Antibody Testing in Pediatric Rheumatology